| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435353000 | Rat (i.e., Rattus) | 33 |
| 20080274543 | Neuronal Cell Propagation Using Rotating Wall Vessel - The present invention provides methods of propagating transformed neurons in a simulated microgravity environment generated by a rotating wall vessel (“3-D culture”) so that the phenotype of the transformed neurons so cultured becomes closer to that of non-transformed neurons (primary neurons) and less like the phenotype of transformed neurons cultured via standard cell culture techniques (“2-D culture”). | 11-06-2008 |
| 20090081780 | CANINE RESPIRATORY CORONAVIRUS (CRCV) SPIKE PROTEIN, POLYMERASE AND HEMAGGLUTININ/ESTERASE - A canine respiratory coronavirus (CRCV) that is present in the respiratory tract of dogs with canine infectious respiratory disease and which has a low level of homology to the enteric canine coronavirus, but which has a high level of homology to all bovine coronavirus strains (e.g., Quebec and LY138) and human coronavirus strain OC43. | 03-26-2009 |
| 20100227397 | Preparation method of a hair dermal papilla cell preparation, composition and method for regenerating hair follicles, and animal having regenerated hair follicles - The present invention provides a method for preparing a hair dermal papilla cell preparation comprising preparing a cell suspension by removing epidermal tissue from skin tissue and subjecting the resulting dermal tissue fraction to collagenase treatment, and cyropreserving the cell suspension to kill the follicular epidermal cells. The present invention also provides a composition for regenerating hair follicles comprising hair dermal papilla cell and epidermal cells, wherein the ratio of the number of hair dermal papilla cell to the number of epidermal cells is from 1:10 to 10:1. | 09-09-2010 |
| 20100233803 | Fusion Polypeptides Capable of Activating Receptors - A fusion polypeptide comprising (A) | 09-16-2010 |
| 20100285579 | PREANTRAL FOLLICLE DERIVED EMBRYONIC STEM CELLS - The present invention relates to a method for producing a preantral follicle-derived embryonic stem cell and a preantral follicle-derived embryonic stem cell. The present method comprises the steps of (a) obtaining a preantral follicle from mammalian ovaries; (b) growing the preantral follicle in vitro; (c) maturing an oocyte in vitro present in the cultured preantral follicle; (d) activating the matured oocyte for parthenogenesis; (e) culturing the activated oocyte to form a blastocyst; and (f) culturing inner cell mass (ICM) cells of the blastocyst to produce the preantral follicle-derived embryonic stem cell. | 11-11-2010 |
| 20100317100 | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state - The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor. | 12-16-2010 |
| 20110014691 | METHOD FOR GENERATING PRIMATE CARDIOVASCULAR PROGENITOR CELLS FOR CLINICAL USE FROM PRIMATE EMBRYONIC STEM CELLS OR EMBRYONIC-LIKE STATE CELLS, AND THEIR APPLICATIONS - The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention. | 01-20-2011 |
| 20110033927 | METHODS OF GENERATING SMALL-DIAMETER TISSUE ENGINEERED BLOOD VESSELS - Methods for generating small diameter tissue engineered blood vessels through direct cell seeding onto tubular templates or mandrels, such as fibrin microthreads or collagen-coated silicon tubes, are described. | 02-10-2011 |
| 20120009672 | Methods for Differentiating Cells into Hepatic Stellate Cells and Hepatic Sinusoidal Endothelial Cells, Cells Produced by the Methods, and Methods for Using the Cells - The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies. | 01-12-2012 |
| 20120115224 | CULTURE METHODS OF BONE MARROW STROMAL CELLS AND MESENCHYMAL STEM CELLS, AND MANUFACTURE METHOD OF GRAFT CELLS FOR CENTRAL NERVE SYSTEM DISEASES THERAPY - In a culture method of the present invention, by culturing bone marrow stromal cells or mesenchymal stem cells under a pseudo micro-gravity environment generated by multi-axis rotation, bone marrow stromal cells or mesenchymal stem cells having an average cell size smaller than that before the culture are obtained. The bone marrow stromal cells or mesenchymal stem cells thus cultured are suitable as graft cells for a central nerve diseases therapy. | 05-10-2012 |
| 20120142092 | RAT EMBRYONIC STEM CELL - The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like. | 06-07-2012 |
| 20120149103 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-14-2012 |
| 20120149104 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-14-2012 |
| 20120149105 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-14-2012 |
| 20120149106 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-14-2012 |
| 20120156774 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-21-2012 |
| 20120156775 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-21-2012 |
| 20120156776 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-21-2012 |
| 20120164728 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 06-28-2012 |
| 20120208271 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 08-16-2012 |
| 20120208272 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 08-16-2012 |
| 20120214231 | Cells Useful for Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines. | 08-23-2012 |
| 20120238014 | Pluripotent Cells from the Mammalian Late Epiblast Layer - The invention relates to the isolation and propagation of pluripotent cells isolated from the mammalian late epiblast layer, termed Epiblast Stem Cells (EpiSCs). These cells are useful in a range of applications, including the generation of transgenic animal species. | 09-20-2012 |
| 20130071924 | CELLS EXHIBITING NEURONAL PROGENITOR CELL CHARACTERISTICS AND METHODS OF MAKING THEM - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells. | 03-21-2013 |
| 20130164839 | METHOD FOR CULTURING CELLS IN A SYSTEM COMPRISING LAMININ-5 - The present invention is directed to providing a method for culturing cells in a system containing laminin-5. The method of the present invention is characterized by a culture system containing a polypeptide selected from a group consisting of: a protein in blood other than extracellular matrix proteins, which is, serum, serum albumin, prealbumin, immunoglobulin, α-globulin, β-globulin, α1-antitrypsin (α1-AT), heptoglobin (Hp), α2-macroglobulin (α2-M), α-fetoprotein (AFP), transferrin, retinol-binding protein (RBP) or adiponectin; gelatin; a protein belonging to a tumor necrosis factor (TNF) family; and peptone. | 06-27-2013 |
| 20130236956 | NUCLEIC ACID FRAGMENTS FROM A RIBOSOMAL PROTEIN PROMOTER FOR ENHANCING GENE EXPRESSION - The present invention relates to nucleic acid fragments and constructs comprising genomic nucleotide sequences from the promoter region of a 60S ribosomal protein L32 gene (RPL32), for the production of a gene product of interest in a eukaryotic, preferably mammalian, host cell in the presence of a stringent selectable marker. The invention further relates to host cells comprising the nucleic acid constructs, to methods for generating the host cells and to methods for producing a gene product of interest using the host cells. | 09-12-2013 |
| 20140045262 | CONSTRUCTS AND METHOD FOR REGULATING GENE EXPRESSION OR FOR DETECTING AND CONTROLLING A DNA LOCUS IN EUKARYOTES - The present invention concerns constructs based on sequences derived from the partitioning system of plasmid and chromosomal DNA of bacteria, such as eukaryotic expression vectors, fusion proteins and polynucleotides encoding the same and also eukaryotic cells transformed with or expressing such constructs. The present invention also concerns the use thereof in the regulation of gene expression and/or in the detection and control of the dynamics, localization or metabolism of genomic DNA loci of interest in eukaryotic cells. | 02-13-2014 |
| 20140356945 | Potential Regenerative Cell and Its Culturing Method - The present invention relates to a type of cell—potential regenerative cell (PRC) capable of continuous proliferation, and generated mammal (including human) cells, tissues and tissue-organs by in vitro culture and replication of PRCs. The present invention also relates to the methods and cell growth regulators for culturing mammal (including human) PRCs, tissues, and tissue-organs. | 12-04-2014 |
| 20150079675 | GENERATION AND MAINTENANCE OF STEM CELLS - The present invention provides for the generation and maintenance of pluripotent cells by culturing the cells in the presence of an ALK5 inhibitor. | 03-19-2015 |
| 20150125951 | Mutant Alpha-Synuclein, and Methods Using Same - The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (A56), at the alanine at position 76 (A76), at the methionine at position 127 (M127) and/or at the valine at position 118 (V118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims. Also, a non-human animal comprising the cell of the invention is provided, as defined in the claims. Finally, the invention provides methods for identifying a substance that prevents or reduces toxicity of alpha-synuclein, as defined in the claims. | 05-07-2015 |
| 20160102281 | HANGING DROP PLATE - A hanging drop plate and a method of cultivating cells or of producing molecular aggregates in at least one liquid volume that adheres to a drop contact area of such a hanging drop plate. The hanging drop plate has a body with a first surface and a second surface that is essentially coplanar to the first surface. The second surface has a drop contact area for adherently receiving a liquid volume. The drop contact area is distinguished from a surrounding area by a relief structure that prevents spreading of the liquid volume on the second surface of the body. The body has at least one conduit that mouths into the drop contact area from the direction of the first surface of the body. A liquid volume is applied to the drop contact area through a communicating conduit. Cells and/or molecules can be introduced into this liquid volume. | 04-14-2016 |
| 20160108360 | GENETIC MODIFICATION OF RATS - Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (ES) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided. Such methods and compositions comprise an in vitro culture comprising a feeder cell layer and a population of rat ES cells or a rat ES cell line, wherein the in vitro culture conditions maintain pluripotency of the ES cell and comprises a media having mouse leukemia inhibitory factor (LIF) or an active variant or fragment thereof. Various methods of establishing such rat ES cell lines are further provided. Methods of selecting genetically modified rat ES cells are also provided, along with various methods to generate a transgenic rat from the genetically modified rat ES cells provided herein. Various kits and articles of manufacture are further provided. | 04-21-2016 |
| 20160177369 | Resonance Energy Transfer Assay with Cleavage Sequence and Spacer | 06-23-2016 |
